4 days Ago By ABMN Staff
Envestnet Asset Management Inc. cut its stake in Repligen Co. ( NASDAQ:RGEN – Free Report ) by 5.
2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,442 shares of the biotechnology company’s stock after selling 5,809 shares during the quarter. Envestnet Asset Management Inc.
owned about 0.19% of Repligen worth $15,321,000 at the end of the most recent quarter. Several other large investors have also recently made changes to their positions in the stock.
Groupama Asset Managment lifted its holdings in shares of Repligen by 12,321.0% during the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after purchasing an additional 400,680 shares during the last quarter.
Raymond James Financial Inc. acquired a new position in Repligen during the 4th quarter valued at about $52,492,000. Allspring Global Investments Holdings LLC raised its stake in Repligen by 79.
9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock valued at $65,395,000 after buying an additional 203,011 shares during the last quarter. Alliancebernstein L.
P. boosted its holdings in Repligen by 23.4% in the fourth quarter.
Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company’s stock worth $145,508,000 after acquiring an additional 191,439 shares in the last quarter.
Finally, Norges Bank purchased a new stake in shares of Repligen during the fourth quarter worth about $24,034,000. 97.64% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth A number of analysts recently commented on the stock. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.
00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, April 4th.
JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.
00 and gave the company an “overweight” rating in a research report on Friday, February 21st. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.
00 price target for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.
00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.
com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $178.64. Insider Transactions at Repligen In other Repligen news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction that occurred on Monday, March 17th.
The stock was bought at an average price of $150.69 per share, with a total value of $37,672.50.
Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This trade represents a 31.
53 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link . Corporate insiders own 1.
20% of the company’s stock. Repligen Stock Down 0.5 % Shares of RGEN stock opened at $126.
62 on Wednesday. The company has a current ratio of 10.44, a quick ratio of 8.
76 and a debt-to-equity ratio of 0.26. Repligen Co.
has a twelve month low of $102.97 and a twelve month high of $182.52.
The stock has a 50 day moving average of $141.72 and a 200 day moving average of $146.05.
The stock has a market cap of $7.11 billion, a P/E ratio of -248.27, a P/E/G ratio of 4.
54 and a beta of 1.27. Repligen ( NASDAQ:RGEN – Get Free Report ) last posted its earnings results on Thursday, February 20th.
The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.
03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.
21%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.
58 million. As a group, sell-side analysts expect that Repligen Co. will post 1.
72 EPS for the current year. Repligen Company Profile ( Free Report ) Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter ..
